CoStasis Stops Bleeding At Hard And Soft Tissue Sites - Cohesion PMA Study
This article was originally published in The Gray Sheet
Executive Summary
Cohesion Technologies plans to file a premarket approval application this spring for its CoStasis surgical hemostat for treatment of bleeding in cardiovascular, hepatic, general and orthopedic surgery procedures, the firm announced Jan. 14.
You may also be interested in...
Cohesion's CoStasis Surgical Hemostat To Ship In July, Gains FDA Approval
Tyco International's U.S. Surgical unit will market Cohesion Technologies' CoStasis liquid surgical hemostat. Shipments are expected to begin in early July.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”